Corbus Pharmaceuticals Holdings, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $22.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-09
- Corbus Pharmaceuticals Holdings, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $22.00M, a 105.61% increase from fiscal 2024.
- Corbus Pharmaceuticals Holdings, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $10.70M, a 0.93% decline from fiscal 2023.
- Corbus Pharmaceuticals Holdings, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $10.80M, a 25.10% increase from fiscal 2022.
- Corbus Pharmaceuticals Holdings, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $8.63M, a 720.63% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $22.00M 10-K · filed 2026-03-09 | |
| 2024-12-31 | $10.70M 10-K · filed 2026-03-09 | |
| 2023-12-31 | $10.80M 10-K · filed 2025-03-11 | $10.81M 10-K · filed 2024-03-12 |
| 2022-12-31 | $8.63M 10-K · filed 2024-03-12 | |
| 2021-12-31 | $1.05M 10-K · filed 2023-03-07 | |
| 2020-12-31 | $23.32M 10-K · filed 2022-03-08 | |
| 2019-12-31 | $18.21M 10-K · filed 2021-03-15 | $18.21M 10-K · filed 2020-03-16 |
| 2018-12-31 | $14.58M 10-K · filed 2020-03-16 | |
| 2017-12-31 | $5.09M 10-K · filed 2019-03-12 | |
| 2016-12-31 | $7.86M 10-K · filed 2018-03-12 | |
| 2015-12-31 | $3.62M 10-K · filed 2017-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |